Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2009-015632-15Phase 3Active
Phase 3, double-blind trial of rivastigmine in delirium (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time until return home or transfer to rehabilitation/post-acute care. Started Sep 2009; status: active.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2009-015632-15.